3M Company (MMM), the diversified industrials and materials conglomerate that sits in both the Dow Jones Industrial Average and the S&P 500, has become one of Wall Street's more closely watched turnaround stories. After roughly two years of beat-and-raise results, the shares trade near $162, leaving investors to weigh whether they can climb about 17% to the $190 average analyst price target.
The central target is not a single firm's call but the average of 12 current targets identified from research published between July and late September 2026. The most bullish cluster sits well above the average: UBS at $218, J.P. Morgan at $205, Goldman Sachs at $202, Wolfe Research at $201, and Bank of America Securities at $200. The neutral middle includes Wells Fargo at $195, Deutsche Bank at $192, Morgan Stanley at $189, Citi at $183, Mizuho at $180, and Bernstein at $171 after a September 25 upgrade to Market Perform. At the low end, RBC Capital remains at Underperform with a target near $132. The raw mean of these figures is about $189, rounded to $190; the overall recommendation skews toward "Buy," though the wide range shows analysts do not agree on how much upside remains.
Recent revisions capture that split. Bernstein's upgrade cited a new "R&D factory" commercialization model and a short-cycle recovery tied to AI (artificial intelligence) capital spending, yet the firm stopped at Market Perform on valuation. J.P. Morgan moved to Overweight in July, while Wells Fargo initiated coverage at Equal-Weight in late September. Bulls argue estimates keep drifting higher; cautious analysts argue much of the turnaround is already reflected in the price.
As of the early October 2026 close, MMM traded near $161.89, below its 52-week high of roughly $184.90. Reaching $190 requires about a 17% rise, which is substantial rather than trivial. The stock's trailing P/E (price-to-earnings ratio) sits near 29, while the forward GAAP P/E is roughly 22, and the forward price-to-sales multiple of about 3.3x runs well above its five-year average of roughly 2.6x. The company raised its full-year 2026 adjusted EPS outlook to about $8.80 to $8.95, and second-quarter adjusted organic growth reached 5.4%, so the earnings foundation has been firm; the question is whether the market will pay a richer multiple to reach $190.
Several fundamentals could help. Two years of beat-and-raise results have built credibility, with second-quarter adjusted EPS of about $2.40 topping the roughly $2.27 consensus estimate. Management is pushing an "R&D factory" model with 350-plus product launches planned for 2026 and about $4 billion in five-year new-product sales, aimed at restoring organic growth. AI and data-center demand is supporting short-cycle and electronics businesses, and adjusted operating margin reached 23.4% in 2025, up 200 basis points year over year. A $7.5 billion buyback authorization, a dividend yielding close to 2%, and steadily rising consensus estimates all give analysts reasons to lift targets.
The clearest overhang is PFAS litigation. The company still faces more than 15,000 personal-injury cases, a prior bellwether trial was vacated, and separate matters such as the Harris County verdict and a New York filing remain unresolved, with no verdict or settlement yet anchoring valuation. Valuation is also stretched relative to history, and the consumer segment contracted slightly in 2025 on weaker discretionary spending. Cost inflation and tariff-related expenses, roughly $12.6 billion in total debt, and adverse foreign-exchange effects add further pressure. A guidance cut, an adverse litigation outcome, or sector rotation away from industrials could all keep the stock short of $190.
Shares have traded between about $139.34 and $184.90 over the past year. The $184–$185 zone marks the prior high and the most immediate resistance; $190 is both the target and a round psychological level just above that high. On the downside, the $155–$160 area and the 52-week low near $139 are the notable support levels. Reaching $190 would require breaking above the recent high and holding new highs, a meaningful structural step rather than a simple continuation of the current range.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions vary. Investors should watch the third-quarter 2026 earnings release, full-year guidance updates, and analyst revisions that follow, along with any PFAS settlement or trial developments. Broader inputs such as industrial purchasing-manager indices, AI and data-center capital spending, and Federal Reserve rate policy will also shape the multiple the market is willing to pay.
For traders who want a more dynamic view than a single analyst price target provides, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart-watching allows. Explore the AI Daily Buy/Sell Signals to see how automated analysis can complement your own research.
The $190 target is the average of 12 current analyst targets spanning roughly $132 to $218, so it represents the center of a genuinely divided street rather than a consensus of conviction. Reaching it requires about a 17% advance from near $162, plus a break above the $184.90 prior high. Strong execution, rising guidance, and AI-driven demand support the case, while unresolved PFAS liability, an elevated valuation, and consumer softness are the main reasons the stock could fall short. The target is a benchmark for evaluating progress, not a promise, and the next earnings report and any litigation news will be the key signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MMM has been loosely correlated with MDU. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MMM jumps, then MDU could also see price increases.
| Ticker / NAME | Correlation To MMM | 1D Price Change % |
|---|---|---|
| MMM | 100% | -2.21% |
| Industrial Conglomerates industry (29 stocks) | 18% Poorly correlated | +0.15% |
| Producer Manufacturing industry (349 stocks) | 5% Poorly correlated | +1.32% |